Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
Rhea-AI Summary
Pulmonx (Nasdaq: LUNG) will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET. A live and archived webcast will be accessible via the Investors section of the Pulmonx website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 15 | Earnings date notice | Neutral | +0.7% | Scheduled second-quarter 2026 results release and conference call for July 29 |
| Jun 01 | Inducement grants | Neutral | +1.3% | Granted 84,300 restricted stock units to 17 newly hired employees |
| Apr 29 | Quarterly earnings | Negative | +6.7% | Reported revenue decline and net loss alongside refinancing and full-year guidance |
| Apr 28 | Conference presentation | Neutral | -2.4% | Announced participation in Bank of America Securities health care conference |
| Apr 15 | Earnings date notice | Neutral | -2.7% | Scheduled first-quarter 2026 results release after market close |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior conference and earnings-date notices were followed by negative or limited moves, while the Q1 results release was followed by a 6.67% increase despite reported revenue declines.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET.
A live and archived webcast of the fireside chat will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX® Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) to commercialize the Zephyr® Endobronchial Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, LungTraX®, StratX®, and Zephyr® are registered trademarks of Pulmonx Corporation.
Contact
Brian Johnston
Gilmartin Group
investors@pulmonx.com
